
    
      Approximately 210 subjects with inadequately controlled T2DM will be recruited from US and
      Canada. Subjects will be randomly assigned to receive bexagliflozin tablets, 20 mg, or
      placebo in a ratio of 2:1 once daily for 24 weeks.
    
  